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OBJECTIVE To assess the hypothesis that patients receiving placebo in overactive bladder (OAB) trials who
experience less benefit from “treatment” continue with behavioral modifications such as fluid re-
striction, whereas those on active treatment adopt more normal drinking patterns. This may mani-
fest itself as a reduction in micturition frequency (MF).
MATERIALS AND
METHODS
We interrogated a large integrated database containing pooled patient data from 4 randomized,
placebo-controlled phase III OAB solifenacin studies. A statistical correction was applied to MF
to remove the influence of fluid intake.
RESULTS Pooled analysis using patient-level data from 3011 patients and accounting for the studies within
the models showed that all patients voided progressively less total urine per 24 hours during treat-
ment than at baseline. However, reduction in total urine volume voided per 24 hours was larger in
patients receiving placebo vs those on solifenacin; with a substantial decrease in 24-hour urine output
in the placebo group from baseline to week 4, which was not the case in active groups. After cor-
recting MF for volume voided for each patient using the statistical correction and averaging the
corrected MF per treatment arm, the placebo effect almost disappeared. Patients on solifenacin voided
less often, with a statistically significant increase in volume voided each time they voided, vs placebo.
CONCLUSION Assuming volume voided is a good surrogate measure for fluid intake, this analysis shows
that fluid restriction almost completely explains the reduction in MF in the placebo group.
In contrast, patients receiving active treatment adopt more normal drinking patterns once
they start to perceive improvement in their OAB symptoms. UROLOGY 106: 55–59, 2017. © 2017
The Authors. Published by Elsevier Inc.
Placebo response is a well-recognized phenomenon inclinical trials, and is generally higher with chronicdisorders, in which patients experience bother or
pain, than in disorders involving objectively measured
parameters.1 A substantial placebo effect is generally ob-
served in overactive bladder (OAB) trials,1-3 making it oc-
casionally difficult to quantify the benefit of active
treatments.4,5
Several hypotheses have been suggested for this sub-
stantial placebo effect. Receiving a placebo is not the
same as “no treatment,” but is part of a package of care in
which patients receive general advice, have their urine
tested for infection and have any infection treated, see
the doctor or nurse who is carrying out the study, fill in a
bladder (micturition) diary on a regular basis, and in
some countries are given free medication, for which they
would otherwise have to pay. Therefore, the placebo re-
sponse seen in these trials could be due to all nondrug
aspects of the trial, in addition to “treatment” with placebo.6
Participating in an OAB clinical trial, which involves
completing bladder diaries, usually for the first time, and
interacting with healthcare professionals inevitably results
in a bladder training effect. Patients also gain a greater
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degree of knowledge and insight into their condition
from reading the patient information leaflets. The bladder
diary gives the patient visual feedback of “performance,”
hence they may also “hold on” to improve the outcome
of the bladder diary, leading to better reported responses.
Patients may also learn to empty their bladders preemp-
tively before a critical volume is reached by adopting a
“just in case” approach to going to the toilet. Another
contributory factor is that patients may seek help when
their symptoms are at their worst, and there may be a
contribution from symptoms tending to naturally return
toward the individual’s baseline norm (regression towards
the mean).6
A part of bladder training is to actively encourage patients
to drink less as part of the educational program. The
International Consultation on Incontinence guidelines
recommend behavioral modifications, including fluid
manipulation, as part of first-line treatment for OAB. The
average fluid intake required for normal bodily functions
is about 24 mL/kg of body weight per day in a temperate
climate7; equating to 1.68 L/d for a 70 kg person. Logically,
an increase in daily fluid intake is related to an increase
in the volume of urine voided daily.8 Conversely, decreasing
fluid intake can improve urinary symptoms in patients with
OAB.7,9,10 A randomized, prospective crossover trial in adults
with OAB symptoms showed that a reduction of 25% in
fluid intake from baseline (median 1854 mL) was effective
in reducing OAB symptoms (daytime urinary frequency,
urgency, and nocturia).11
It was hypothesized that patients in a placebo group,
who experience less benefit from their “treatment,” continue
with behavioral modifications (such as fluid restriction),
whereas those in the active group, who benefit from treat-
ment, adopt a more normal drinking pattern. Therefore,
fluid restriction itself in the placebo group may contrib-
ute to the placebo response, which is demonstrated as a
reduction in micturition frequency (MF). We also postu-
lated that there would be a difference in voided volumes
between the placebo and treatment groups as a result of
the fluid restriction. To assess the evidence supporting
our hypothesis, we interrogated a large integrated data-
base containing pooled patient data from 4 randomized,
placebo-controlled, fixed-dose solifenacin monotherapy
studies.
MATERIALS AND METHODS
All 4 studies were 12-week, placebo-controlled, double-blind, fixed-
dose monotherapy phase IIIa studies (Supplementary Table S1).12-15
A manuscript describing methodology for the large integrated da-
tabase has been published.16
Study endpoints based on MF can be affected directly by study
medication, but may also be altered by changes in fluid intake
over the course of the study. For example, if an individual has
10 micturitions per 24 hours with a fluid intake of 2 L, then one
would expect them to have 5 micturitions per 24 hours with a
fluid intake of 1 L. If the same individual has 7 micturitions per
24 hours with a fluid intake of 1 L, then this can be considered
worsening of OAB symptoms even if the absolute number of
micturitions has decreased. Correction of MF follows the same
principle, correcting in alignment with each individual’s fluid
intake at baseline and endpoint, using the following statistical
correction:
MF MF at baselinebase =
MVV mean volume voided micturition MVV
at baseline
base = ( )
TotVV total volume voided TotVV
per hours at baseline
base = ( )
24
MF MF at end of treatment EoT or final visitEoT = ( )
MVV MVV at EoTEoT =
TotVV TotVV per hours at EoTEoT = 24
TotVVEoT can be separated into 2 parts by regarding it as being
equal to TotVVbase plus the change from baseline to EoT in TotVV:
that is TotVV TotVV TotVVEoT base, = + Δ
where ΔTotVV = TotVVEoT – ToTVVbase.
As MVV is, by definition, equal to TotVV/MF, by rearrange-










VEoT TotVV MVVEoT+ Δ .
This can be viewed as a partition of MFEoT into 2 parts as follows:
ΔTotVV/MVVEoT is the additional number of micturitions per
24 hours (vs baseline) required to void the extra fluid intake.
TotVVbase/MVVEoT is the number of micturitions per 24 hours
that would be required at EoT to void the total daily volume, if
this total volume remained unchanged from baseline, that is, if
treatment did not affect subjects’ fluid intake.
By applying this statistical correction, the size of the placebo
effect in each evaluable patient in the dataset can be assessed.
Differences between treatment arms in total volume voided at
the end of the study were analyzed using an analysis of covari-
ance with treatment arm and baseline as covariate.
RESULTS
The integrated database comprised pooled data from 3011
patients (Table 1). Average total urine voided over a
24-hour period for the combined solifenacin 5 mg and 10 mg
groups is shown in Table 2. Baseline values were lower for
the solifenacin 5 mg group than for the other 2 groups
(Table 1), but were relatively high overall (approximately
1700 mL). Pooled analysis of the patient data from the
integrated database showed that those taking so-
lifenacin voided progressively less total urine per 24
hours during the treatment period than at baseline (Fig. 1).
However, the reduction in total urine volume voided per
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24 hours was larger in patients in the placebo arm (P < .0001),
compared with those receiving active treatment; with a
substantial decrease in 24-hour urine output recorded
for the placebo group from baseline to week 4, which
was not the case in the active groups. A reduction in MF
from baseline to EoT was seen in both active and place-
bo groups; however, after correcting MF for patients in
relation to their volume voided and then averaging the cor-
rected MF per treatment arm using the statistical
correction described in the Materials and Methods section,
this showed a stronger correction in the placebo arm
than in the active treatment arm, such that the placebo
effect almost completely disappeared (Fig. 2). Patients
on solifenacin voided less often, with a statistically
Table 1. Baseline demographics and OAB characteristics (full analysis set)
Solifenacin 5 mg (N = 552) Solifenacin 10 mg (N = 1158) Placebo (N = 1137)
Men, N (%) 121 (21.9) 242 (20.9) 219 (19.3)
Women, N (%) 431 (78.1) 916 (79.1) 918 (80.7)
Age, mean (SD) years 56.8 (13.6) 57.9 (13.5) 58.1 (13.2)
Age range, years 19-85 18-86 18-88
Age group, years (%)
18 to <40 55 (10.0) 115 (9.9) 99 (8.7)
40 to <65 315 (57.1) 640 (55.3) 640 (56.3)
65 to <75 130 (23.6) 277 (23.9) 277 (24.4)
≥75 52 (9.4) 126 (10.9) 121 (10.6)
BMI, mean (SD) 27.2 (5.0) 28.5 (6.3) 28.5 (6.4)
Region, N (%)
United States/Canada 0 604 (52.2) 604 (53.1)
Europe 429 (77.7) 429 (37.0) 409 (36.0)
Other 123 (22.3) 125 (10.8) 124 (10.9)
BMI, body mass index; OAB, overactive bladder; SD, standard deviation.
Table 2. Average total urine volume voided over 24-hour period (mL)
Combined Solifenacin 5 mg
and 10 mg Groups Placebo
Average total urine
volume voided (mL) N SD
Average total urine
volume voided (mL) N SD
Baseline 1772.29 1709 711.16 1829.25 1134 775.47
Week 4 1762.61 1703 719.22 1729.27 1134 752.24
Week 8 1725.32 1614 704.44 1703.61 1066 776.79
Week 12 1695.11 1557 677.28 1679.88 1021 745.17
SD, standard deviation.






































Figure 1. Mean change from baseline to weeks 4, 8, and































































Figure 2. Change from baseline to end of study in micturi-
tion frequency per 24 hours.
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significant increase in volume voided each time they voided,
compared with placebo.
DISCUSSION
A Cochrane review of anticholinergic drugs vs placebo for
OAB in adults calculated that 41% of subjects allocated
to placebo report symptomatic improvement in symptoms
vs 56% in patients allocated to active treatment.3 In
addition, a systematic review of placebo-controlled,
randomized trials in OAB showed that subjects who
received placebo demonstrated statistically significant
improvements from baseline in micturitions per day and
incontinence episodes per day.17 In common with other
OAB trials, a large placebo effect has been observed in
solifenacin studies. The solifenacin integrated database con-
tains a large number of patients (>3000) from multiple
studies conducted all over the world. Pooled analysis of this
large integrated database showed that there was a greater
reduction in volume voided over 24 hours in the placebo
arm than in the active arms. The logical assumption being
that volume voided is a good surrogate measure for fluid
intake, one can estimate the impact of reduced fluid intake
on MF. It is clear from the results reported here that after
adjusting for fluid intake using the statistical correction,
the placebo effect almost completely disappears, and the
difference between the placebo and active groups becomes
bigger.
We therefore suggest that a significant component of the
clinical benefit perceived by patients receiving placebo is
largely due to behavioral modifications to restrict their fluid
intake, which they continue throughout the duration of
the trials. However, patients receiving active treatment are
able to return to a more “normal” drinking pattern once
they start to perceive an improvement in their OAB symp-
toms; as a therapeutic consequence of solifenacin is to in-
crease bladder capacity.18 The return to normal fluid intake
in the active treatment group will naturally numerically
increase the number of micturitions per 24 hours com-
pared with when the patient was in a fluid-restricted state.
This can limit differentiation between active treatment and
placebo for number of micturitions per 24 hours and is also
interpreted as a high placebo effect.
It should be noted in this database that baseline values
for total volumes voided were relatively high. However,
baseline values were lower in the solifenacin 5 mg group
compared with the other groups. A possible explanation
for the lower baseline values in the solifenacin 5 mg group
may be that this dosing group is mainly used in European
studies, whereas the 10 mg group is mainly used in US
studies (Table 1). The US population, especially women,
generally drinks more than Europeans. For example, between
1977 and 1996, there was a dramatic increase in fluid con-
sumption in the United States (the consumption of bottled
water increased 908% and the average soft drink portion
increased by 48%).19,20
Limitations of this analysis are that the studies did not
document changes in patient weight during the study, and
that there was no direct measurement of fluid intake for
any of the studies; currently, however, there is no consen-
sus on how to measure total fluid intake with or without
water from food.21 In addition, we do not know if fluid intake
had an effect on other OAB symptoms. Since the key symp-
toms of OAB are interlinked, it is possible that fluid intake
may impact other symptoms of the OAB symptom complex
including urgency or urgency urinary incontinence and con-
tribute to the high placebo response seen in patients.12-15
It is possible that patients in the active treatment arm
increased their daily fluid intake as a result of experienc-
ing dry mouth as an adverse event. However, a recent study
examining the impact of dry mouth on fluid intake and
OAB symptoms in women receiving fesoterodine for 10
weeks found that women experiencing dry mouth did not
change their total fluid intake. In contrast, women without
dry mouth significantly reduced their fluid intake (mean
decrease of 172.1 mL).22
Theoretically, a micturition diary would have a bladder
training effect in both placebo and active groups. To confirm
these observations, future studies would need to include
micturition diaries and measure fluid intake and voided
volumes. Although frequency and volume charts would
provide an accurate record of fluid intake and output, asking
patients to accurately record fluid intake may add signifi-
cant burden in already complex clinical trials.
CONCLUSION
Active treatment was more effective than placebo in these
trials. However, a high placebo effect is witnessed in OAB
trials and therefore the purpose of this study was to explore
a hypothesis to explain this placebo effect. Urinary volume
voided over 24 hours is a good surrogate measure for fluid
intake, assuming that environmental conditions do not fluc-
tuate excessively leading to increased fluid loss. There-
fore, fluid restriction could explain the reduction in MF
in the placebo group and provides an alternative expla-
nation for the placebo effect in OAB trials. We believe that
it is therefore likely that a significant part of the clinical
benefit perceived by patients receiving placebo is derived
from behavioral modifications to restrict fluid intake, which
continues throughout the duration of the trials. In con-
trast, patients receiving active treatment are, as a conse-
quence of the therapeutic benefit derived from the drug,
able to adopt more normal drinking patterns once they start
to perceive improvement in their OAB symptoms. This
return to normal fluid intake will naturally increase the
number of micturitions per day compared to when the
patient was in a fluid-restricted state. This can limit dif-
ferentiation between active treatment and placebo for
number of micturitions per day and is interpreted as a high
placebo effect.
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